Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Ruxolitinib

An inhibitor of the JAK1 and JAK2 kinases, which relay the signals of many growth factors and of inflammation: approved in the United States in 2011 for myelofibrosis, it is also used in polycythaemia vera and graft-versus-host disease. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?As a cream, in 2022 it became the first medicine approved in the United States to restore skin colour in vitiligo.

RuxolitinibGo to the active ingredient →
RuxolitinibActive ingredientRuxolitinibCat. No. P-R100-001CAS 941678-49-5

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.